Elypta raises funds to develop multi-cancer early detection test
The company has two studies in progress, LEVANTIS-0087A for MCED and AURORAX-0087A for kidney cancer recurrence.

The company has two studies in progress, LEVANTIS-0087A for MCED and AURORAX-0087A for kidney cancer recurrence.
M.I.Tech has developed a family of conformable, self-expanding metal stents called HANAROSTENT.
The Fassier-Duval Telescopic Intramedullary System corrects deformity of long bones while preventing or stabilising fractures.
The transaction is expected to expand ResMed’s SaaS business footprint outside the US.
Through the acquisition, BD will have access to a new pharmacy automation market segment worth $600m.
Debt offerings in the medical sector have seen an increase of 20% from H2 2020 to H2 2021, an analysis…
ByPartnerships in the medical sector have seen a decrease of 50% from H2 2020 to H2 2021, an analysis of…
ByThe test identifies gene expression profiles that indicate specific cancers by interrogating mRNA from a whole blood sample.
Thank you for subscribing to Medical Device Network